Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × urelumab × Dermatologic × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2 Lymphoid 2 Thoracic 1 Sarcoma 1 Plasma cell 1 Head & Neck 1 Gastrointestinal 1 Dermatologic 1 CNS 1

Conditions

Interventions

pembrolizumab 89 Cyclophosphamide 65 Nivolumab 61 Ipilimumab 59 fludarabine 32 aldesleukin 27 fludarabine phosphate 25 Vemurafenib 24 Interleukin-2 24 Biopsy 20 trametinib 19 dabrafenib 15 Radiotherapy 15 Temozolomide 14 Magnetic Resonance Spectroscopy 14 Filgrastim 14 Cisplatin 14 atezolizumab 12 Specimen Handling 12 Gemcitabine 12 Carboplatin 11 spartalizumab 10 romidepsin 10 poly ICLC 10 Peripheral Blood Stem Cell Transplantation 10 Paclitaxel 10 Introns 10 Etoposide 10 CTLA-4 Antigen 10 Bevacizumab 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00803374 2011-11-21

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

Bristol-Myers Squibb

Phase 1 Withdrawn

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡